Rad Tech CE, ASRT, ARRT® CE, Category A Credits | Radiology Continuing Education

Approvals/Requirements Satisfied by eRADIMAGING Courses

  • ASRT approval for ARRT Category A credit
  • All Courses eligible of international radiographers' CPD requirements
  • ASRT and MDCB are approved continuing education providers of ARRT and all courses are accepted by ARRT
  • California CE requirements met for all radiography courses
  • NMTCB accepted (All Courses)
  • All Courses available for RRAs
  • ARMRIT accepted (All MRI Courses)
  • MDCB approval by the Medical Dosimetrist Certification (Selected Courses)
  • Florida approval for all courses 1 credit or more
  • ARDMS accepted (All Courses)
  • CAMRT and Sonography Canada recognize the ASRT approval (All Courses)
  • Approval: This course is approved by ASRT and MDCB - approved continuing education providers of ARRT.
  • Release Date: 7/30/2019
  • Expiration Date: 7/30/2022
  • Credit Hours: 1 Credit
  • Course Description and objectives:

    Course Description
    Mortality rates for patients with breast cancer have trended downward over the past several decades due in part to the heightened use of breast-conserving therapy (BCT) in women with early stage or noninvasive disease. Central to the BCT strategy has been adjuvant radiotherapy, particularly via brachytherapy accelerated partial breast irradiation (APBI). In brachytherapy, radioactive isotopes are inserted into or near the tumor bed, minimizing the exposure to normal surrounding tissue and organs at risk. Low-dose brachytherapy regimens were the standard for many years, but recently, high dose-rate (HDR) sources and fractionations have become preferable, as they have been shown to be safer, more convenient, and offer comparable or superior efficacy. Brachytherapy APBI has also become a more sophisticated treatment delivery approach with new software algorithms and imaging modalities yielding more refined and optimized treatment plans. Questions remain, however, about cosmetic outcomes using HDR isotopes, while the most effective delivery techniques and dose fractionations for specific populations, as well as the optimal approaches to achieve maximum local control and minimal toxicity are yet to be determined.

    Learning Objectives
    After reading this article, the participant should be able to:

    • EXPLAIN the advantages and disadvantages of high-dose rate brachytherapy as a radiotherapeutic option in patients with breast cancer.
    • DEFINE the primary imaging and brachytherapy modalities and their roles in treatment planning and patient selection.
    • ASSESS the merits of potential advances now in development and proposed refinements to current practices.

     

    Categories: Radiation therapy/dosimetry, Treatment, Computed Tomography (CT), Mammography

  • CE Information:

    In order to receive CE credit, you must first complete the activity content. When completed, go to the "Take CE Test!" link to access the post-test.

    Submit the completed answers to determine if you have passed the post-test assessment. You must answer 6 out of 8 questions correctly to receive the CE credit. You will have no more than 3 attempts to successfully complete the post-test.

    Participants successfully completing the activity content and passing the post-test will receive 1.0 ARRT Category A credit.

    Approved by the American Society of Radiologic Technologists for ARRT Category A credit.

    Approved by the state of Florida for ARRT Category A credit.

    Texas direct credit.

    This activity may be available in multiple formats or from different sponsors. ARRT does not allow CE activities such as Internet courses, home study programs, or directed readings to be repeated for CE credit in the same biennium.


Brachytherapy and Breast Cancer: Best Practices in Imaging-Based Patient Selection, Treatment Planning...

Steven Marks*

*President, MedCom Consultants, Inc, Potomac, MD

Address correspondence to: Steven Marks, MedCom Consultants Inc, 1311 Fallsmead Way, Potomac, MD 20854. Email: steven.marks52@gmail.com

Disclosure statement: Steven Marks reports having no financial or advisory relationship with any corporate, medical, or political organization doing work related to this paper or other business activity at MedCom Consultants, Inc.

 ABSTRACT

Mortality rates for patients with breast cancer have trended downward over the past several decades due in part to the heightened use of breast-conserving therapy (BCT) in women with early stage or noninvasive disease. Central to the BCT strategy has been adjuvant radiotherapy, particularly via brachytherapy accelerated partial breast irradiation (APBI). In brachytherapy, radioactive isotopes are inserted into or near the tumor bed, minimizing the exposure to normal surrounding tissue and organs at risk. Low-dose brachytherapy regimens were the standard for many years, but recently, high dose-rate (HDR) sources and fractionations have become preferable, as they have been shown to be safer, more convenient, and offer comparable or superior efficacy. Brachytherapy APBI has also become a more sophisticated treatment delivery approach with new software algorithms and imaging modalities yielding more refined and optimized treatment plans. Questions remain, however, about cosmetic outcomes using HDR isotopes, while the most effective delivery techniques and dose fractionations for specific populations, as well as the optimal approaches to achieve maximum local control and minimal toxicity are yet to be determined.

View the full content

Sample eRADIMAGING Course *

* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.

Become a member

Satisfy your CE requirements today!

Join now

We offer special group rates, call or email.

908-253-9001

webmaster@eradimaging.com

Newsletter

Enter your email address to receive our new course alerts.